Chronic kidney disease+1
RecruitingA study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease
A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease
- Disease:Chronic kidney diseaseArteriosclerosis
- Substances:Orforglipron hemicalcium
Slovakia- Participants:18–64 years · 65+ years
- Substances:Orforglipron hemicalcium
- Sponsor:Eli Lilly & Co.






